MCC950 Sodium
别名: CP-456773 Sodium, CRID3 Sodium
目录号:S7809 Purity: 99.98%
MCC950 Sodium是一种有效的、选择性NLRP3抑制剂,在骨髓来源的巨噬细胞中IC50为7.5 nM。对AIM2, NLRC4或NLRP1炎症体没有作用。
CAS: 256373-96-3
客户使用Selleck的MCC950 Sodium发表文献158篇
- Circ Res, 2024 135(9):933-950
- Signal Transduct Target Ther, 2020 5(1):235
- Gastroenterology, 2020 158(1):253-269
- Nat Microbiol, 2019 4(5):789-799
- Immunity, 2018 49(4):740-753
- Bone Res, 2024 12(1):53
- J Neuroinflammation, 2024 21(1):276
- Int J Biol Sci, 2024 20(9):3393-3411
- Cell Death Dis, 2024 15(5):360
- Cell Rep, 2024 43(4):113981
- Cell Rep, 2024 43(3):113954
- PLoS Pathog, 2024 20(8):e1012387
- Int Immunopharmacol, 2024 141:112935
- J Innate Immun, 2024 1-25.
- J Inflamm Res, 2024 17:10769-10784
- Biology (Basel), 2024 13(2)87
- Biochem Biophys Res Commun, 2024 736:150870
- Int J Oral Sci, 2024 16(1):3
- bioRxiv, 2024 2024.04.19.589802
- bioRxiv, 2024 2024.03.27.586885
- Gut Microbes, 2023 15(1):2192478
- J Exp Clin Cancer Res, 2023 42(1):26
- J Neuroinflammation, 2023 20(1):112
- Cell Rep, 2023 42(2):112116
- Cell Chem Biol, 2023 S2451-9456(23)00335-5
- Ecotoxicol Environ Saf, 2023 252:114630
- iScience, 2023 26(10):107942
- Molecules, 2023 10.3390/molecules28227527
- Vet Res, 2023 54(1):78
- Acta Biochim Biophys Sin (Shanghai), 2023 55(12):1961-1971
- Res Sq, 2023 rs.3.rs-3318233
- bioRxiv, 2023 2023.06.01.543248
- Bone Res, 2022 10(1):5
- Cell Death Dis, 2022 13(1):38
- Cell Rep, 2022 38(10):110489
- Cell Rep, 2022 41(10):111742
- Cell Rep, 2022 41(4):111532
- Am J Transplant, 2022 10.1111/ajt.16968
- Inflamm Regen, 2022 42(1):24
- Thromb Res, 2022 214:8-15
- Oxid Med Cell Longev, 2022 2022:2566917
- PLoS Pathog, 2022 18(8):e1010787
- Cells, 2022 11(22)3579
- Cells, 2022 11(1)134
- Int J Mol Sci, 2022 23(15)8306
- Int Immunopharmacol, 2022 108:108757
- J Cell Physiol, 2022 10.1002/jcp.30663
- J Virol, 2022 96(14):e0212721
- Ann N Y Acad Sci, 2022 1508(1):92-104
- Chin Med, 2022 17(1):17
- Cell Signal, 2022 93:110304
- Vet Res, 2022 53(1):6
- Toxicol Appl Pharmacol, 2022 440:115954
- Front Cardiovasc Med, 2022 9:748183
- Free Radic Res, 2022 1-13
- Nat Commun, 2021 12(1):4664
- Nat Commun, 2021 12(1):3964
- EBioMedicine, 2021 75:103803
- Metabolism, 2021 118:154748
- J Neuroinflammation, 2021 18(1):295
- J Neuroinflammation, 2021 18(1):163
- J Neuroinflammation, 2021 18(1):66
- Cell Death Dis, 2021 12(10):871
- Cell Death Dis, 2021 12(1):87
- Acta Pharmacol Sin, 2021 10.1038/s41401-021-00749-7
- Elife, 2021 10e70938
- EMBO Rep, 2021 e50743
- Biomed Pharmacother, 2021 143:112133
- Cell Biosci, 2021 11(1):82
- Thromb Res, 2021 199:1-9
- Free Radic Biol Med, 2021 167:243-257
- Free Radic Biol Med, 2021 165:171-183
- Front Immunol, 2021 12:767508
- Front Immunol, 2021 12:753092
- Immunology, 2021 10.1111/imm.13402
- Glia, 2021 10.1002/glia.23963
- Food Funct, 2021 10.1039/d1fo01746b
- Front Pharmacol, 2021 12:743086
- Int Immunopharmacol, 2021 99:107962
- Front Pharmacol, 2021 12:646265
- Am J Physiol Cell Physiol, 2021 321(6):C964-C977
- Front Cell Dev Biol, 2021 9:779432
- Int J Mol Med, 2021 47(2):607-620
- J Cell Mol Med, 2021 10.1111/jcmm.16863
- Virulence, 2021 12(1):1362-1376
- Food Chem Toxicol, 2021 S0278-6915(21)00805-X
- J Neurotrauma, 2021 10.1089/neu.2020.7481
- Exp Dermatol, 2021 10.1111/exd.14432
- BMC Anesthesiol, 2021 21(1):104
- Autophagy, 2020 10.1080/15548627.2020.1850609
- J Med Virol, 2020 10.1002/jmv.26329
- Bone Res, 2020 18;8:10
- J Neuroinflammation, 2020 17(1):205
- Cell Death Dis, 2020 11(10):901
- Cell Death Dis, 2020 17;11(4):239
- Cell Rep, 2020 31;30(13):4370-4385e7
- Arterioscler Thromb Vasc Biol, 2020 40(3):751-765
- Phytomedicine, 2020 80:153398
- J Dent Res, 2020 22034520933533
- Free Radic Biol Med, 2020 148:140-150
- Front Immunol, 2020 11:619096
- Int J Radiat Oncol Biol Phys, 2020 22 pii: S0360-3016(20)31039-7
- Front Pharmacol, 2020 11:541426
- Int Immunopharmacol, 2020 17;84:106501
- Int Immunopharmacol, 2020 83:106394
- Front Cell Dev Biol, 2020 8:608
- Front Microbiol, 2020 11:1881
- Inflammation, 2020 10.1007/s10753-020-01289-8
- J Inflamm (Lond), 2020 17:22
- Am J Physiol Endocrinol Metab, 2020 10.1152
- Front Mol Biosci, 2020 3;7:37
- J Mol Cell Cardiol, 2020 139:75-86
- Toxicology, 2020 432:152392
- J Immunol, 2020 ji2000703
- Neurochem Res, 2020 45(2):437-454
- Biosci-Rep, 2020 30;40-4-pii:-BSR20194118
- Brain Res Bull, 2020 164:55-64
- Mol Immunol, 2020 16;122:80-88
- Exp Eye Res, 2020 12;196:108065
- Cancer Manag Res, 2020 12:8413-8424
- Biochem Biophys Res Commun, 2020 521(4):933-938
- J Nucl Cardiol, 2020 10.1007
- Adv Wound Care (New Rochelle), 2020 1;9(5):219-232
- Nat Commun, 2019 10(1):3473
- PLoS Biol, 2019 17(9):e3000354
- Pharmacol Res, 2019 147:104339
- Cell Prolif, 2019 e12701
- Free Radic Biol Med, 2019 137:24-36
- Oxid Med Cell Longev, 2019 2019:3753485
- Front Immunol, 2019 10:1872
- Front Immunol, 2019 10:1925
- Apoptosis, 2019 24(9-10):703-717
- PLoS Pathog, 2019 15(6):e1007795
- Clin Sci (Lond), 2019 133(4):565-582
- Int Immunopharmacol, 2019 74:105575
- Int Immunopharmacol, 2019 70:147-155
- J Cell Mol Med, 2019 23(11):7360-7371
- Lab Invest, 2019 99(6):749-763
- Invest Ophthalmol Vis Sci, 2019 60(8):3034-3045
- Toxicol Sci, 2019 10.1093/toxsci/kfz099
- Acta Biochim Biophys Sin (Shanghai), 2019 51(5):501-508
- J Physiol Biochem, 2019 10.1007/s13105-019-00702-7
- Diabetes Metab Syndr Obes, 2019 12:1297-1309
- Med Sci Monit, 2019 25:8515-8526
- Biochem Biophys Res Commun, 2019 519(2):402-408
- Evid Based Complement Alternat Med, 2019 2019:2969364
- Prostate, 2019 10.1002/pros.23866
- Int J Clin Exp Pathol, 2019 12(4):1324-1332
- EMBO Mol Med, 2018 10(4)
- JCI Insight, 2018 3(7)
- J Invest Dermatol, 2018 138(6):1380-1390
- Biochem Pharmacol, 2018 154:278-292
- J Biol Chem, 2018 293(48):18454-18465
- BMC Complement Altern Med, 2018 18(1):192
- Mol Immunol, 2018 104:11-19
- Biochem Biophys Res Commun, 2018 503(4):3031-3037
- J Exp Med, 2017 214(11):3219-3238
- Arthritis Rheumatol, 2017 69(8):1636-1646
化学信息&溶解度
分子量 | 426.46 |
分子式 | C20H23N2O5S.Na |
CAS号 | 256373-96-3 |
Smiles | CC(C)(C1=COC(=C1)S(=O)(=O)[N-]C(=O)NC2=C3CCCC3=CC4=C2CCC4)O.[Na+] |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
Water : 43 mg/mL Ethanol : 43 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 85 mg/mL Ethanol : 85 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 85 mg/mL Ethanol : 85 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 85 mg/mL Ethanol : 85 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 85 mg/mL Ethanol : 85 mg/mL DMSO : Insoluble ( DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
saline
浓度:43mg/ml
(100.83mM)
操作示例:以 1 mL 工作液为例,取 43mg该产品加到1ml生理盐水(0.9% NaCL溶液)中,混合均匀使其澄清,请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。